Search
Hepatitis B immune globulin
go.drugbank.com/drugs/DB05276ApprovedInvestigationalDuring the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus. … Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B.
Products: HEPATECT®CP 500 UI (INMUNOGLOBULINA HUMANA CONTRA EL VIRUS DE LA HEPATITIS B)., HEPATECT ® CP 2000 U.IX 40ML (INMUNOGLOBULINAHUMANAHIPERINMUNECONTRA EL VIRUS DE LA HEPATITIS B)Sennosides
go.drugbank.com/drugs/DB11365ApprovedInvestigationalSennoside A, one of the sennosides present in the laxative medication, has recently proven effective in inhibiting the ribonuclease H (RNase H) activity of human immunodeficiency virus (HIV) reverse transcriptase … It typically begins working in minutes when given by rectum and within twelve hours when given by mouth[FDA Label]. It is a weaker laxative than bisacodyl or castor oil[A177092].
Mixtures: EX-lax Gentle Strength, Laxatif De Sene Et Docusate De SodiumProducts: Senna Gen, EX-lax Maximum Strength Stimulant LaxativeRanitidine
go.drugbank.com/drugs/DB00863ApprovedWithdrawn[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. … [A176843] Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related
Products: RANITIDINA 50MG EN SODIO CLORURO 0.7 % POR 50 ML INFUSION, RANITIDINA 50 MG EN SODIO CLORURO 0.7% POR 100 ML (INFUSION)Carboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigationalCarboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982. … [A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Categories: Compounds used in a research, industrial, or household settingProducts: PLATINWAS 150 MG 10MG/ML ENJ. FLAKON, 1 ADET, PLATINWAS 450 MG 10MG/ML ENJ. FLAKON, 1 ADETCoagulation Factor IX Human
go.drugbank.com/drugs/DB13152ApprovedInvestigationalFactor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Categories: coagulation factor IX, II, VII and X in combinationSodium bicarbonate
go.drugbank.com/drugs/DB01390ApprovedInvestigationalSodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
Mixtures: ENO, E-Z-gas IIProducts: BICARBONATO DE SODIO EN POLVO - 45Chlorpheniramine
go.drugbank.com/drugs/DB01114ApprovedInvestigationalA histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications.
Mixtures: COUGH - EN, COUGH - EN PLUSSynonyms: 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine, 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamineEtanercept
go.drugbank.com/drugs/DB00005ApprovedInvestigationalEtanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.
Products: BENEPALI 50MG ILO I E FER, ENBREL MYCLIC PEN 50 MG ENJ. COZ.ICIN KULLANIMA HAZIR KALEM, 12 ADETNiacin
go.drugbank.com/drugs/DB00627ApprovedInvestigationalNutraceuticalNiacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
Mixtures: AVi MULTIVITAMIN with Zinc, Real Ginger, Lemon and Lemongrass, Pro Enz TabProducts: Niaspan ERLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050
Categories: Drugs Used in DiabetesProducts: LINAGLIPTIN EG